Learning Objectives​​​​

1.            To define the attributes of disease-modifying therapies (DMTs) that are important to patients with MS

2.            To identify factors influencing patients’ willingness-to-pay (WTP) for DMTs

3.            To examine discrete choice experiment (DCE) as a patient-centered value assessment method



Click here to complete today’s evaluation: https://ce.icep.wisc.edu/neurology-grand-rounds-20-22-eval-15135

Session date: 
11/29/2021 - 4:00pm to 5:00pm CST
Medical Foundation Centennial Bldg, Room #1220
1685 Highland Ave
Madison, WI 53705
United States
  • 1.00 AMA PRA Category 1 Credit
  • 1.00 University of Wisconsin–Madison Continuing Education Hours
    • 1.00 Approved for AMA PRA Category 1 Credit™

Please login or register to take this course.
Discloser List CME Internal Report